IQVIA has announced its launch of the IQVIA Patient Portal, a global web-based solution built on the Salesforce Health Cloud platform.
“Patient communities are clear about what matters most to them, roughly 90 percent want access to information about their participation in the study including updates about the outcome of a study,” said Cynthia Verst, president, Design and Delivery Innovation, Research & Development Solutions at IQVIA.
Trial participants are invited to join the IQVIA Patient Portal when they are recruited. Upon enrollment, they are guided through the trial process with study visit and medication reminders, disease education, and concierge and travel support services. In addition, they are provided access to the individual lab results from their participation and other general information relating to the study as approved by the sponsor and investigator. Upon trial completion, patients receive a plain language summary of the study. Additionally, patients can join an alumni community where they can continue to engage with clinical research through future trial participation opportunities.
IQVIA’s geographic scale addresses the regulatory and compliance needs of customers regardless of where the study takes place, and retention solutions are built specifically for each clinical trial location with relevant study-level content.
The IQVIA Patient Portal is part of IQVIA’s full-service clinical trial offering or as a stand-alone solution.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.